HRP20110570T1 - Amidi diazabicikloalkana selektivni na podvrstu nikotinskih acetilkolinskih receptora - Google Patents

Amidi diazabicikloalkana selektivni na podvrstu nikotinskih acetilkolinskih receptora Download PDF

Info

Publication number
HRP20110570T1
HRP20110570T1 HR20110570T HRP20110570T HRP20110570T1 HR P20110570 T1 HRP20110570 T1 HR P20110570T1 HR 20110570 T HR20110570 T HR 20110570T HR P20110570 T HRP20110570 T HR P20110570T HR P20110570 T1 HRP20110570 T1 HR P20110570T1
Authority
HR
Croatia
Prior art keywords
disorder
compound
dementia
disorders
composition
Prior art date
Application number
HR20110570T
Other languages
English (en)
Croatian (hr)
Inventor
Mazurov Anatoly
Miao Lan
Xiao Yun-De
Original Assignee
Targacept
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept filed Critical Targacept
Publication of HRP20110570T1 publication Critical patent/HRP20110570T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20110570T 2006-11-02 2011-08-02 Amidi diazabicikloalkana selektivni na podvrstu nikotinskih acetilkolinskih receptora HRP20110570T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85607906P 2006-11-02 2006-11-02
PCT/US2007/083330 WO2008057938A1 (en) 2006-11-02 2007-11-01 Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes

Publications (1)

Publication Number Publication Date
HRP20110570T1 true HRP20110570T1 (hr) 2011-09-30

Family

ID=39233054

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110570T HRP20110570T1 (hr) 2006-11-02 2011-08-02 Amidi diazabicikloalkana selektivni na podvrstu nikotinskih acetilkolinskih receptora

Country Status (33)

Country Link
US (6) US8114889B2 (de)
EP (2) EP2284171B1 (de)
JP (2) JP5539723B2 (de)
KR (2) KR20100124356A (de)
CN (4) CN102838605B (de)
AR (2) AR063451A1 (de)
AT (2) ATE509022T1 (de)
AU (2) AU2007317433B2 (de)
BR (2) BRPI0717930A2 (de)
CA (1) CA2663925C (de)
CL (1) CL2007003155A1 (de)
CO (1) CO6180435A2 (de)
CY (1) CY1112374T1 (de)
DK (1) DK2094703T3 (de)
ES (2) ES2395212T3 (de)
HK (2) HK1149751A1 (de)
HR (1) HRP20110570T1 (de)
IL (2) IL197618A (de)
MX (1) MX2009004801A (de)
MY (2) MY156730A (de)
NO (1) NO20091251L (de)
NZ (2) NZ575557A (de)
PE (2) PE20081441A1 (de)
PL (1) PL2094703T3 (de)
PT (1) PT2094703E (de)
RS (1) RS51834B (de)
RU (2) RU2448969C2 (de)
SA (1) SA07280584B1 (de)
SI (1) SI2094703T1 (de)
TW (3) TWI404532B (de)
UA (2) UA98944C2 (de)
UY (1) UY30686A1 (de)
WO (1) WO2008057938A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI404532B (zh) * 2006-11-02 2013-08-11 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
US20110071180A1 (en) * 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
WO2009113950A1 (en) * 2008-03-10 2009-09-17 Astrazeneca Ab Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist
JP5502077B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規な化合物
EP2280705B1 (de) 2008-06-05 2014-10-08 Glaxo Group Limited Neue verbindungen
EP2300437B1 (de) 2008-06-05 2013-11-20 Glaxo Group Limited Benzpyrazolderivate als inhibitoren von pi3-kinasen
EP2344496A1 (de) * 2008-09-05 2011-07-20 Targacept Inc. Amide aus diazabicyclooctanen und verfahren zu ihrer verwendung
WO2010028011A1 (en) * 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
EP2406255B1 (de) 2009-03-09 2015-04-29 Glaxo Group Limited 4-oxadiazol-2-ylindazole als inhibitoren von pi3-kinasen
JO3025B1 (ar) 2009-04-30 2016-09-05 Glaxo Group Ltd الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
RU2417082C2 (ru) * 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
CN102741239B (zh) 2009-11-18 2015-06-24 苏文生命科学有限公司 作为α4β2烟碱型乙酰胆碱受体配体的双环化合物
DK2519514T3 (en) 2009-12-29 2015-11-16 Suven Life Sciences Ltd Neuronal nicotinic alpha4beta2-acetylcholine receptor ligands
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
MY187449A (en) 2013-11-26 2021-09-22 Hoffmann La Roche New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
DK3122750T3 (da) 2014-03-26 2019-11-04 Hoffmann La Roche Bicykliske forbindelser som autotaxin (ATX)- og lysofosfatidsyre (LPA)-produktionshæmmere
EA035335B1 (ru) 2014-10-20 2020-05-28 Ойстер Поинт Фарма, Инк. Способы лечения офтальмологических расстройств с применением варениклина
JP6886967B2 (ja) 2015-09-04 2021-06-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft フェノキシメチル誘導体
BR112018006024A2 (pt) 2015-09-24 2020-05-12 F. Hoffmann-La Roche Ag Compostos bicíclicos como inibidores de atx
CN107614505B (zh) * 2015-09-24 2021-05-07 豪夫迈·罗氏有限公司 作为双重atx/ca抑制剂的新型二环化合物
JP6876685B2 (ja) 2015-09-24 2021-05-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Atx阻害剤としての二環式化合物
MA42923A (fr) * 2015-09-24 2021-04-28 Hoffmann La Roche Composés bicycliques comme inhibiteurs mixtes de atx/ca
JP7090551B2 (ja) 2016-04-07 2022-06-24 オイスター ポイント ファーマ インコーポレイテッド 眼状態の治療方法
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
KR102296703B1 (ko) 2017-03-20 2021-09-01 포르마 세라퓨틱스 인크. 피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
US20230055923A1 (en) 2018-09-19 2023-02-23 Forma Therapeutics, Inc. Activating pyruvate kinase r

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU482990A1 (ru) * 1973-09-03 1978-04-15 Предприятие П/Я Г-4059 Способ получени 1,4-диазабицикло(2,2,2)-октана
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5468858A (en) 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
KR100197454B1 (ko) * 1993-12-29 1999-06-15 디. 제이. 우드, 스피겔 알렌 제이 디아자비시클릭 뉴로키닌 길항제
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
JP2003516988A (ja) * 1999-12-14 2003-05-20 ニューロサーチ、アクティーゼルスカブ 新規ヘテロアリール−ジアザビシクロアルカン類
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
EP1368354A1 (de) 2001-03-07 2003-12-10 Pfizer Products Inc. Modulatoren der aktivität von chemokin-rezeptoren
NZ529880A (en) * 2001-07-06 2005-09-30 Neurosearch As Novel compounds, their preparation and use
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
CN1317280C (zh) * 2003-02-27 2007-05-23 神经研究公司 新的二氮杂双环芳基衍生物
JP2006519208A (ja) * 2003-02-27 2006-08-24 ニューロサーチ、アクティーゼルスカブ 新規ジアザビシクロアリール誘導体
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US7365193B2 (en) * 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
AU2005251891A1 (en) * 2004-06-09 2005-12-22 F. Hoffmann-La Roche Ag Octahydro-pyrrolo[3,4-C] derivatives and their use as antiviral compounds
EP1768987B1 (de) 2004-07-22 2009-04-01 Cumbre Pharmaceuticals Inc. (r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen
ZA200709626B (en) * 2005-05-13 2009-02-25 Lexicon Pharmaceuticals Inc Multicyclic compounds and methods of their use
TWI404532B (zh) * 2006-11-02 2013-08-11 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺

Also Published As

Publication number Publication date
IL209026A (en) 2014-03-31
MY156730A (en) 2016-03-15
US8268860B2 (en) 2012-09-18
TW201114424A (en) 2011-05-01
CN102838605B (zh) 2017-04-26
NZ587847A (en) 2011-09-30
AU2010219323B2 (en) 2012-05-03
CN101528745A (zh) 2009-09-09
RU2009138600A (ru) 2011-04-27
US8114889B2 (en) 2012-02-14
AR079840A2 (es) 2012-02-22
CN102942569B (zh) 2015-10-28
BRPI0722387A2 (pt) 2023-02-23
RU2448969C2 (ru) 2012-04-27
ATE509022T1 (de) 2011-05-15
UA106718C2 (uk) 2014-10-10
RS51834B (en) 2012-02-29
PE20081441A1 (es) 2008-10-30
CA2663925A1 (en) 2008-05-15
US8859609B2 (en) 2014-10-14
SI2094703T1 (sl) 2011-07-29
TWI405763B (zh) 2013-08-21
MX2009004801A (es) 2009-07-31
RU2009120674A (ru) 2010-12-10
CN102020646A (zh) 2011-04-20
TW200826935A (en) 2008-07-01
KR20100124356A (ko) 2010-11-26
WO2008057938A1 (en) 2008-05-15
NO20091251L (no) 2009-05-28
CN102838605A (zh) 2012-12-26
PL2094703T3 (pl) 2011-10-31
SA07280584B1 (ar) 2010-11-02
JP5539723B2 (ja) 2014-07-02
AU2007317433A1 (en) 2008-05-15
US8921410B2 (en) 2014-12-30
CN101528745B (zh) 2011-09-14
AR063451A1 (es) 2009-01-28
HK1133260A1 (en) 2010-03-19
CN102942569A (zh) 2013-02-27
BRPI0717930A2 (pt) 2011-05-10
IL197618A0 (en) 2009-12-24
EP2094703A1 (de) 2009-09-02
JP2010509230A (ja) 2010-03-25
MY145602A (en) 2012-03-15
US20100081683A1 (en) 2010-04-01
IL197618A (en) 2013-09-30
ES2395157T3 (es) 2013-02-08
TW201305176A (zh) 2013-02-01
UY30686A1 (es) 2009-08-03
ATE545646T1 (de) 2012-03-15
CY1112374T1 (el) 2015-12-09
HK1149751A1 (en) 2011-10-14
AU2010219323A1 (en) 2010-09-30
US20100173932A1 (en) 2010-07-08
CN102020646B (zh) 2013-11-13
CA2663925C (en) 2015-04-21
UA98944C2 (ru) 2012-07-10
EP2094703B1 (de) 2011-05-11
EP2284171B1 (de) 2012-02-15
JP2013056919A (ja) 2013-03-28
KR101415705B1 (ko) 2014-07-04
US20130005789A1 (en) 2013-01-03
TWI454262B (zh) 2014-10-01
ES2395212T3 (es) 2013-02-11
US9580434B2 (en) 2017-02-28
NZ575557A (en) 2011-01-28
PT2094703E (pt) 2011-07-22
US20120289572A1 (en) 2012-11-15
RU2517693C2 (ru) 2014-05-27
DK2094703T3 (da) 2011-08-29
TWI404532B (zh) 2013-08-11
EP2284171A1 (de) 2011-02-16
US20160039833A1 (en) 2016-02-11
PE20110671A1 (es) 2011-10-20
IL209026A0 (en) 2011-01-31
US20150080576A1 (en) 2015-03-19
CO6180435A2 (es) 2010-07-19
JP5739398B2 (ja) 2015-06-24
KR20090074051A (ko) 2009-07-03
CL2007003155A1 (es) 2008-05-16
AU2007317433B2 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
HRP20110570T1 (hr) Amidi diazabicikloalkana selektivni na podvrstu nikotinskih acetilkolinskih receptora
RU2012140148A (ru) (2s,3r)-n-(2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)бензофуран-2-карбоксамид, новые солевые формы и способы их применения
ATE458736T1 (de) Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken, verfahren zu deren herstellung und pharmazeutische zusammensetzungen,die diese enthalten
RU2008148325A (ru) Полиморфные формы(2s)-(4е)-n-метил-5-(3-изопропоксипиридин)ил) 4-пентен-2амина для лечения расстройств центральной нервной системы
WO2006053039A3 (en) Hydroxybenzoate salts of metanicotine compounds
ATE447571T1 (de) Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken; verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält
IL159843A0 (en) Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2007040438A3 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
EP1820503A3 (de) Als Kinaseinhibitoren aktive Aminoindazol-Derivate, Herstellungsverfahren dafür und pharmazeutische Zusammensetzungen damit
MXPA02012164A (es) Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden.
ATE353013T1 (de) Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
GEP20084417B (en) Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
NO20091888L (no) Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav
DE602005008633D1 (de) Imidazoä1,5aütriazoloä1,5dübenzodiazepin-derivative zur behandlung kognitiver störungen
WO2008077557A8 (en) 8-ethinylxanthine derivatives as selective a2a receptor antagonists
HRP20130007T1 (hr) Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli
MXPA05009719A (es) Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
RU2005141060A (ru) Метаболит кветиапина
US20210198218A1 (en) Compounds for therapeutic use
MX2007007472A (es) Derivados de triazolona, tetrazolona e imidazolona para uso como antagonista del adrenorreceptor alfa-2c.
DK2091942T3 (da) Substituerede pyrazinderivater til anvendelse som en medicin
PL1658081T3 (pl) Pochodne pterydyny o działaniu immunosupresyjnym
WO2007135131A8 (en) Substituted pyrazinone derivatives for use as a medicine
WO2009148290A3 (en) 3-substituted propanamine compounds